Oragenics, Inc. focuses on the discovery, development, and commercialization of various technologies associated with oral health, antibiotics, and other general health benefits. It develops and markets probiotic products comprising ProBiora3, an oral care probiotics that promote oral health for humans and pets under the Evora and ProBiora brands in approximately 13 countries worldwide. The company's ProBiora3 products include flavored probiotic tablets, such as EvoraPlus and EvoraKids for daily use by adults and children; EvoraPet for companion pets, including cats and dogs; and EvoraPro, a product for the dental office channel. Its product candidates consists of LPT3-04, a naturally occurring compound for weight loss; SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay; and MU1140-S, an antibiotic product candidate in preclinical testing for healthcare-associated infections. Oragenics, Inc. offers its ProBiora3 products through direct-to-consumer channels, professional offices, and private label partnerships. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
Can-Fite BioPharma, Ltd., a clinical-stage biotechnology company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis, as well as completed Phase II study for the treatment of rheumatoid arthritis; completed Phase III study for the treatment of dry eye; completed Phase II study for the treatment of glaucoma; and initiating a Phase II study of CF101 for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of liver cancer; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company is headquartered in Petah-Tikva, Israel.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its hematopoietic stem cell (HSC) modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person's lifespan; and satellite cell modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person's lifespan. The company's lead product candidate includes ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical development for hematologic malignancies. It is developing pharmacologically optimized HSC therapeutics for the treatment of lysosomal storage disorders within the central nervous system; and Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Radio One, Inc., together with its subsidiaries, operates as an urban-oriented multi-media company in the United States. The company operates through four segments: Radio Broadcasting, Reach Media, Internet, and Cable Television. The Radio Broadcasting segment is engaged in the radio broadcasting operations that primarily targets African-American and urban listeners. As of December 31, 2013, it owned and operated 54 broadcast stations located in 16 urban markets. The Reach Media segment is involved in the operation of the Tom Joyner Morning Show; and other syndicated programming assets comprising The Rickey Smiley Morning Show, The Russ Parr Morning Show, The Yolanda Adams Morning Show, The James Fortune Show, and The Reverend Al Sharpton Show. The Internet segment is engaged in online business, including the operation of Interactive One, an online platform that provides social content, news, information, and entertainment through branded sites, such as News One, UrbanDaily, and HelloBeautiful; and online social networking Websites, including BlackPlanet and MiGente. The Cable Television segment operates an African-American targeted cable television network. The company was founded in 1980 and is based in Silver Spring, Maryland.
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company, develops various targeted and programmable therapeutics. It is developing Accurins that are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. The company's lead Accurin drug candidate includes BIND-014, a prostate-specific membrane antigen targeted Accurin that contains docetaxel and is in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. It has collaboration agreements to develop Accurins based on therapeutic payloads from their product pipelines with Amgen, Inc.; Pfizer Inc.; and AstraZeneca AB. The company was formerly known as BIND Biosciences, Inc. and changed its name to BIND Therapeutics, Inc. in April 2013. BIND Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Ring Energy, Inc. is engaged in the exploration, development, and production of oil and gas in Texas and Kansas. As of December 31, 2013, the company's proven reserves consisted of 7.3 million barrel of oil equivalent. It also has interests in approximately 3,482 gross developed acres and 10,893 gross undeveloped acres in Texas; and 16,997 gross acres in Kansas. Ring Energy, Inc. sells its oil and natural gas production to end users, marketers, and other purchasers. The company was formerly known as Transglobal Mining Corp. and changed its name to Ring Energy, Inc. in March 2008. Ring Energy, Inc. was founded in 2004 and is headquartered in Midlands, Texas.
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology treatments that address major unmet medical needs to advance cancer care. Its commercial product includes Abstral, a sublingual tablet, which is used as treatment option for breakthrough cancer pain in patients. The company's lead product candidate comprise NeuVax (nelipepimut-S or E75), which has completed Phase III clinical trials for preventing the recurrence of breast cancer; and Phase IIb clinical trials in combination with Herceptin for the treatment of breast cancer. It also develops GALE-301 or Folate Binding Protein (FBP), a therapeutic target that has completed Phase II clinical trials for the treatment of ovarian and endometrial cancers; and GALE-401 (Anagrelide CR), which has completed Phase I studies for the treatment of essential thrombocythemia. Galena Biopharma, Inc. has strategic partnership with Dr. Reddy's Laboratories Ltd. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in Lake Portland, Oregon.
First Majestic Silver Corp. acquires, develops, and explores mineral properties with a focus on silver projects in Mxico. The company owns and operates five producing mines, including the La Encantada silver mine in Coahuila State, the La Parrilla silver mine in Durango State, the San Martin silver mine in Jalisco State, the La Guitarra silver mine in Mxico State, and the Del Toro silver mine in Zacatecas State; and two advanced-stage development silver projects, such as the La Luz silver project in San Luis Potosi State and the Plomosas silver project in Sinaloa State. It also owns and operates four exploration projects comprising the Peasco Quemado silver project in Sonora State, the La Frazada silver project in Nayarit State, and the Los Lobos silver project in Sonora State; and has interest in certain exploration properties in Jalisco State, Mxico. The company was formerly known as First Majestic Resource Corp. and changed its name to First Majestic Silver Corp. in November 2006. First Majestic Silver Corp. was founded in 1979 and is headquartered in Vancouver, Canada.
PhotoMedex, Inc., a skin health company, provides integrated disease management and aesthetic solutions to dermatologists, professional aestheticians, and consumers in North America, the Asia Pacific, Europe, and South America. The company operates in three segments: Consumer, Physician Recurring, and Professional. It offers products and services that address skin diseases and conditions, including psoriasis, vitiligo, acne, and photo damage. The company also provides a range of home-use devices under the no!no! brand name for various indications, such as hair removal, acne treatment, skin rejuvenation, and lower back pain; and a professional product line for acne clearance, skin tightening, psoriasis care, and hair removal to physician clinics and spas. In addition, it offers XTRAC excimer lasers used for the treatment of psoriasis and other skin diseases; NEOVA skin care products for preventing premature skin aging due to ultraviolet-induced DNA damage; and Omnilux light therapy systems to treat wrinkles, acne, minor muscle pain, and pigmented lesions. Further, the company provides Lumire light therapy equipment for use in non-medical applications, as well as a line of topical lotions to improve the appearance of fine lines, wrinkles, skin tone, and blemishes. Additionally, it develops, manufactures, and sells surgical products, including proprietary free-beam and Contact Laser systems for surgery; sells surgical disposables and accessories to hospitals and surgery centers; and repairs, maintains, and replaces parts on its products. PhotoMedex, Inc. was founded in 1980 and is headquartered in Horsham, Pennsylvania.
Axion Power International, Inc. is engaged in the design, development, manufacture, and sale of advanced energy storage devices, components, and systems based on its patented PbC Technology. Its PbC batteries and components are used in energy system storage functions. The company also manufactures standard and specialty lead-acid batteries. Axion Power International, Inc. was founded in 2003 and is based in New Castle, Pennsylvania.